Nab-rapamycin (ABI-009)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Nab-rapamycin (ABI-009), covering 2025-02-17 to 2025-02-17. Get the full timeline:
Most recent: Clinical Trial Update: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers [Phase 1, Phase 2]